A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis
Since the structure of DHAR is not available, the enzymatic mechanism is not well-understood and remains poorly characterized
[DOI] [PubMed] [Google Scholar] 168.Kirsch C, Eckert GP, Koudinov AR, Muller WE
By JJ Luime, BW Koes, IJM Hendriksen, A Burdorf, AP Verhagen, HS Miedema, JAN Verhaar | Year: 2004 | Scandinavian Journal of Rheumatology | Volume: 33 | Issue: 2 | Page: 73-81 | Digital Object Identifier: 10.1080/03009740310004667 -------- Disclaimer: The information in this blog post about treating shoulder pain is provided for general informational purposes only and may not reflect current medical thinking or practices
Moleculaire profielen van beide componenten De blend bevat twee structureel en functioneel onderscheiden peptiden
HPLC-verified purity, lot-traceable COA, RUO-grade